Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.


Optimizing the Timing and Sequencing of Regorafenib and TAS-102 for Patients With Metastatic Colorectal Cancer

Listen to Joleen Hubbard, MD, and John L. Marshall, MD, discuss the use of key later-line treatment options for patients with mCRC, including optimal treatment sequencing and dosing and key adverse events.
person default
Joleen Hubbard, MD
John L. Marshall, MD
Released: April 29, 2021

In this episode, Joleen Hubbard, MD, and John L. Marshall, MD, discuss use of the later-line treatment options regorafenib and TAS-102 for patients with mCRC, with topics including:

  • Key data supporting the clinical use of these agents
  • Optimal sequencing and timing of use
  • Dosing considerations
  • Key adverse events


Joleen Hubbard, MD
Associate Professor
Gastrointestinal Oncologist
Medical Oncology
Mayo Clinic
Rochester, Minnesota

John L. Marshall, MD
Chief, Division of Hematology/Oncology
Department of Medicine
Georgetown University Hospital
Washington, DC


Supported by an educational grant from
Bayer HealthCare Pharmaceuticals Inc.

Related Content

Latest data on nivolumab plus chemotherapy or ipilimumab for untreated advanced esophageal cancer (CheckMate 648) from ASCO 2021 reported by Clinical Care Options (CCO)

Released: June 11, 2021

Data from ASCO 2021 on the CheckMate 649 trial of first-line nivolumab + chemotherapy for gastroesophageal cancer, as reported by Clinical Care Options (CCO)

Released: June 10, 2021

Get a preview of key studies being presented at ASCO 2021 from experts in solid tumors and hematologic malignancies from Clinical Care Options (CCO)

person default Angeles Alvarez Secord, MD Michael A. Davies, MD, PhD Ian W. Flinn, MD, PhD Shaji K. Kumar, MD Evan J. Lipson, MD Joyce O'Shaughnessy, MD Daniel P. Petrylak, MD Zofia Piotrowska, MD, MHS Elizabeth R. Plimack, MD, MS Karen L. Reckamp, MD, MS Manish A. Shah, MD Eunice S. Wang, MD Released: June 2, 2021

Expert video on new and established therapies targeting HER2/HER3 in gastrointestinal cancers, from Clinical Care Options (CCO)

Mark D. Pegram, MD
Program Director
Michael F. Press, MD, PhD
Program Director
Daniel Catenacci, MD
Physicians: maximum of 0.5 AMA PRA Category 1 Credits ABIM MOC: maximum of 0.5 Medical Knowledge MOC point(s) Released: May 27, 2021 Expired: May 26, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.